The results of superior control of recurrences of breast cancer in postmenopausal patients with aromatase inhibitors compared to tamoxifen (17–20) paved the way for aromatase inhibitors to become the agents of choice for the adjuvant therapy in postmenopausal patients, although with adverse effects on bone density. Here, CYP19A1 is linked to breast carcinoma.